Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2707]

The Co-BRIM study: Quality-of-life assessment in patients with metastatic...

Prof Brigitte Dreno - Nantes University Hospital, Nantes, France

The Co-BRIM study: Quality-of-life assessment in patients with metastatic melanoma ( Prof Brigitte Dreno - Nantes University Hospital, Nantes, France )

Benefit and risk analysis from the phase III OPTiM trial

Dr Kevin Harrington - Institute of Cancer Research, London, UK

Benefit and risk analysis from the phase III OPTiM trial ( Dr Kevin Harrington - Institute of Cancer Research, London, UK )

Progress in targeted therapy of melanoma

Prof Keith Flaherty - Massachusetts General Hospital, Boston, USA

Progress in targeted therapy of melanoma ( Prof Keith Flaherty - Massachusetts General Hospital, Boston, USA )

Why is screening for melanoma important?

Prof Iris Zalaudek - Medical University of Graz, Graz, Austria

Why is screening for melanoma important? ( Prof Iris Zalaudek - Medical University of Graz, Graz, Austria )

Management of acute metastatic melanoma

Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK

Management of acute metastatic melanoma ( Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK )

How should we handle talimogene laherparepvec (T-VEC)?

Prof Axel Hauschild - University of Kiel, Kiel, Germany

How should we handle talimogene laherparepvec (T-VEC)? ( Prof Axel Hauschild - University of Kiel, Kiel, Germany )

New challenges in drug combination and strategies

Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK

New challenges in drug combination and strategies ( Dr Paul Lorigan - The Christie NHS Foundation Trust, Manchester, UK )

Editor's choice for October 2015

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

Editor's choice for October 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Targeting N-RAS mutated tumours

Prof Axel Hauschild - University of Kiel, Kiel, Germany

Targeting N-RAS mutated tumours ( Prof Axel Hauschild - University of Kiel, Kiel, Germany )

HVEM expression in melanoma metastasis: prognosis correlation

Prof Daniel Olive - Marseilles Cancer Research Center, Marseilles, France

HVEM expression in melanoma metastasis: prognosis correlation ( Prof Daniel Olive - Marseilles Cancer Research Center, Marseilles, France )

Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma

Prof Axel Hauschild - University of Kiel, Kiel, Germany

Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma ( Prof Axel Hauschild - University of Kiel, Kiel, Germany )

Preventing cancer in the EU through legislation, education and taxation

John Ryan - Health and Food Safety Directorate General, European Commission

Preventing cancer in the EU through legislation, education and taxation ( John Ryan - Health and Food Safety Directorate General, European Commission )

More from ecancer